Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification
Description
Today’s episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a trending topic in the field! You will hear leading experts Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discuss what makes mutCALR an attractive therapeutic target in MPNs. Following this, John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, and Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outline the early results of the clinical trial investigating a mutant CALR-targeted antibody, INCA33989, which were presented as a late breaking abstract at the recent 30th Congress of the European Hematology Association (EHA). Additionally, Prof. Harrison comments on other targeted therapies being evaluated in MPNs. Finally, Alex Rampotas, MBBS, MRCP, University College London, London, UK, and Zoë Wong, BSc, University of Oxford, Oxford, UK, provide insight into the development and evaluation of a novel CAR T-cell therapy targeting mutCALR in myelofibrosis (MF).
United States
